Loading clinical trials...
Loading clinical trials...
A Phase 2, 24-Week, Randomized, Double-blind, Placebo-controlled, Multicenter Study, With an 80-Week Active Treatment Extension, to Evaluate the Efficacy and Safety of CC-90001 in Subjects With Idiopathic Pulmonary Fibrosis
Conditions
Interventions
CC-90001
Placebo
Locations
112
United States
Loma Linda Univ Medical Center
Loma Linda, California, United States
Cedars Sinai Medical Center Rheumatology
Los Angeles, California, United States
Local Institution - 514
Sacramento, California, United States
University of California Davis Health System
Sacramento, California, United States
Stanford University Pulmonary and Critical Care Clinic
Stanford, California, United States
University of Florida
Gainesville, Florida, United States
Start Date
July 26, 2017
Primary Completion Date
December 24, 2021
Completion Date
December 24, 2021
Last Updated
June 28, 2023
NCT07417553
NCT04469439
NCT06154447
NCT07265544
NCT06329401
NCT06984679
Lead Sponsor
Celgene
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions